Al­fasig­ma snares EU rights to blood clot­ting an­ti­body on the hunt for pa­tients tak­ing As­traZeneca's Bril­in­ta

Two years af­ter Phase I da­ta gen­er­at­ed promise for ben­tracimab as the first drug to stop bleed­ing in pa­tients that were pre­scribed As­traZeneca’s much-hyped stroke …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER